1. Home
  2. KBON vs CYRX Comparison

KBON vs CYRX Comparison

Compare KBON & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KBON

Karbon Capital Partners Corp. Class A Ordinary Shares

N/A

Current Price

$10.07

Market Cap

442.4M

Sector

Finance

ML Signal

N/A

CYRX

CryoPort Inc.

HOLD

Current Price

$9.95

Market Cap

419.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBON
CYRX
Founded
2025
1999
Country
United States
United States
Employees
N/A
1100
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
442.4M
419.3M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
KBON
CYRX
Price
$10.07
$9.95
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$12.94
AVG Volume (30 Days)
17.7K
406.1K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
156.22
EPS
N/A
1.40
Revenue
N/A
$176,177,000.00
Revenue This Year
N/A
$11.06
Revenue Next Year
N/A
$8.45
P/E Ratio
N/A
$6.89
Revenue Growth
N/A
N/A
52 Week Low
$10.04
$5.21
52 Week High
$10.15
$11.45

Technical Indicators

Market Signals
Indicator
KBON
CYRX
Relative Strength Index (RSI) 54.78 70.69
Support Level $10.05 $9.18
Resistance Level $10.08 $10.23
Average True Range (ATR) 0.02 0.42
MACD 0.00 0.19
Stochastic Oscillator 37.50 88.01

Price Performance

Historical Comparison
KBON
CYRX

About KBON Karbon Capital Partners Corp. Class A Ordinary Shares

Karbon Capital Partners Corp is a blank check company.

About CYRX CryoPort Inc.

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

Share on Social Networks: